Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidelines for qualifying suppliers

This article was originally published in The Tan Sheet

Executive Summary

The Joint Standardized Information on Dietary Supplement Ingredients Working Group issues a new Certificate of Analysis Guideline, the latest in a series of voluntary guidelines for the supplement industry. The guidelines assist finished product manufacturers in qualifying their ingredient suppliers. The guide outlines the type and scope of data that suppliers should include in the CoA they provide manufacturers, said SIDI, a coalition of dietary supplement industry trade associations, in a May 20 release. Andrew Shao, a spokesman for the SIDI Working Group and a senior VP with the Council for Responsible Nutrition, noted that supplement manufacturers rely on supplier CoAs to ensure finished products comply with GMPs. "It's essential for ingredient suppliers to have a form that can be consistently used, containing the appropriate information in a clear and concise format," Shao noted. The coalition said the guidelines will benefit both ingredient suppliers and dietary supplement manufacturers. CRN previously called on FDA to help it develop ingredient supplier qualification guidelines, including standardization of what information should appear on CoAs, to help thwart economically motivated adulteration (1"The Tan Sheet" Aug. 17, 2009)

You may also be interested in...

Fight Adulteration With Supplier Qualification Guide, Supplement Industry Says

The Council for Responsible Nutrition calls on FDA to work with industry on a tool that will help thwart economically motivated adulteration - ingredient supplier qualification guidelines

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts